Celltrion to unveil next-generation antibody drug technologies at AACR 2025

Celltrion and Celltrion Pharm said that they will jointly participate in the 2025 American Association for Cancer Research (AACR) Annual Meeting, set to take place from April 25 to 30 in Chicago.

Celltrion is scheduled to present preclinical results of its multispecific antibody candidate, CT-P72, for the first time in an oral presentation on April 27 (local time).

Co-developed with U.S.-based biotech firm Abpro, CT-P72 is a HER2-targeted T cell engager (TCE) that links HER2-positive tumor cells with T cells, thereby triggering immune-mediated cancer cell destruction.

As a multispecific antibody therapy, CT-P72 is distinct from the company’s previously disclosed antibody-drug conjugate (ADC) programs and marks a major milestone in Celltrion’s expansion into innovative oncology modalities.

Celltrion Pharm will showcase its proprietary dual-payload ADC platform, CTPH-02, in a poster session on April 30.

The platform incorporates two different cytotoxic payloads with distinct mechanisms of action, designed to enhance both the potency and precision of cancer therapy. This will be the first public disclosure of the company's progress in ADC payload engineering.

The upcoming AACR presentations signal Celltrion Group’s strategic pivot toward high-value drug modalities, with Celltrion focusing on novel therapeutic pipelines and Celltrion Pharm advancing enabling platform technologies.

Looking ahead, Celltrion aims to submit investigational new drug (IND) applications for 13 new candidates by 2028, including nine in the ADC category and four multispecific antibody programs. The company plans to leverage its established expertise in antibody engineering—highlighted by the development of the world’s first antibody biosimilar—to cement its position as a leader in innovative biologics.

Notably, Celltrion recently received IND clearance from the U.S. Food and Drug Administration (FDA) for CT-P70, an ADC targeting c-MET, a receptor implicated in tumor growth. This IND marks the beginning of a broader clinical rollout, with Celltrion also planning to file INDs for CT-P71, CT-P73, and CT-P72 later this year.

“AACR 2025 will serve as a pivotal moment for both Celltrion and Celltrion Pharm, as we present breakthrough achievements in next-generation antibody therapeutics,” a Celltrion Group official said. “With robust R&D capabilities and execution, we aim to accelerate the development of novel treatment options and reinforce our trajectory toward becoming a global biopharma leader.”